Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 13/10/17 at 10:36am

It's been another packed week in the industry, with one of the biggest takeaways being that childhood obesity has rocketed up ten-fold over the last 40 years.

Another shocking discovery this week revealed that, of 103 UK companies, pharma giant GlaxoSmithKline was the worst in terms of criteria for good governance, according to a report by the Institute of Directors.

But the biggest news that struck a chord with our readers this week is the revelation that China, in a bid to accelerate its flagging approval record, will begin to accept trial data from overseas in its regulatory decisions.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Childhood obesity increased 10-fold over last four decades

An analysis of childhood and teenage obesity levels around the world have revealed that the numbers who are considered dangerously overweight has spiked enormously over the last four decades.

9. Harnessing the power of the immune system

Dr Áine McCarthy, Senior Science Information Officer at Cancer Research UK, discusses the latest efforts to further understand the immunotherapies that have done so much for cancer treatment in recent years, and how they can be pushed to achieve even more

8. NICE gives final draft guidance on two key cancer drugs

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the treatment of gastrointestinal stromal tumours, and Roche’s Erivedge (vismodegib) in the treatment of advanced basal cell carcinoma.

7. Moffitt scientists discover new applications for Novartis's Zykadia

Researchers at the Moffitt Cancer Center have announced that they have identified the already FDA-approved ceritinib to provide anti-cancer benefits in previously unidentified targets.  

6. AbbVie hit with $140m fine over fraudulent marketing of Androgel

AbbVie has been stung with a $140 million damages award to a man that suffered a heart attack after using its product Androgel, a testosterone replacement therapy.

5. Allergan settles gender discrimination case for $4m

It could have been much worse for Allergan, after it agreed to pay $4 million to resolve a lawsuit alleging gender discrimination - in a case that has stretched back five years.

4. AstraZeneca's Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC

AstraZeneca's Tagrisso has been awarded Breakthrough Therapy Designation by the FDA for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

3. GSK ranked at bottom of ‘good governance’ report

A new report emerging from the Institute of Directors placed UK pharma giant, GSK, in last place out of 103 companies in regards to its own specific criteria for good governance for UK companies.

2. Bayer forced to halt huge study into key drug

Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of Xarelto into the treatment of recent embolic stroke of undetermined source.

1. China to accelerate drug approvals with overseas trial data

In a bid to speed up access to medicines for patients, China has revealed it intends to incorporate data from clinical trials conducted overseas into its approval process for new drugs.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches